rs150672767

Variant summary

Our verdict is Benign. Variant got -13 ACMG points: 0P and 13B. BP4_StrongBP6BS1BS2

The NM_002838.5(PTPRC):​c.3670G>A​(p.Val1224Ile) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00149 in 1,611,676 control chromosomes in the GnomAD database, including 9 homozygotes. In-silico tool predicts a benign outcome for this variant. 12/19 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. V1224V) has been classified as Likely benign.

Frequency

Genomes: 𝑓 0.0015 ( 0 hom., cov: 32)
Exomes 𝑓: 0.0015 ( 9 hom. )

Consequence

PTPRC
NM_002838.5 missense

Scores

2
13

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:2B:6

Conservation

PhyloP100: 0.0820
Variant links:
Genes affected
PTPRC (HGNC:9666): (protein tyrosine phosphatase receptor type C) The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitosis, and oncogenic transformation. This PTP contains an extracellular domain, a single transmembrane segment and two tandem intracytoplasmic catalytic domains, and thus is classified as a receptor type PTP. This PTP has been shown to be an essential regulator of T- and B-cell antigen receptor signaling. It functions through either direct interaction with components of the antigen receptor complexes, or by activating various Src family kinases required for the antigen receptor signaling. This PTP also suppresses JAK kinases, and thus functions as a regulator of cytokine receptor signaling. Alternatively spliced transcripts variants of this gene, which encode distinct isoforms, have been reported. [provided by RefSeq, Jun 2012]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -13 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.004925579).
BP6
Variant 1-198755930-G-A is Benign according to our data. Variant chr1-198755930-G-A is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 440224.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=1, Uncertain_significance=2, Benign=2}. Variant chr1-198755930-G-A is described in Lovd as [Likely_benign].
BS1
Variant frequency is greater than expected in population amr. gnomad4 allele frequency = 0.0015 (228/151960) while in subpopulation AMR AF= 0.00164 (25/15258). AF 95% confidence interval is 0.00114. There are 0 homozygotes in gnomad4. There are 101 alleles in male gnomad4 subpopulation. Median coverage is 32. This position pass quality control queck.
BS2
High Homozygotes in GnomAdExome4 at 9 AR gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
PTPRCNM_002838.5 linkuse as main transcriptc.3670G>A p.Val1224Ile missense_variant 33/33 ENST00000442510.8 NP_002829.3 P08575-3

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
PTPRCENST00000442510.8 linkuse as main transcriptc.3670G>A p.Val1224Ile missense_variant 33/331 NM_002838.5 ENSP00000411355.3 P08575-3

Frequencies

GnomAD3 genomes
AF:
0.00150
AC:
228
AN:
151842
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00114
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00164
Gnomad ASJ
AF:
0.0176
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.0000949
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00125
Gnomad OTH
AF:
0.00431
GnomAD3 exomes
AF:
0.00194
AC:
485
AN:
250252
Hom.:
1
AF XY:
0.00208
AC XY:
282
AN XY:
135264
show subpopulations
Gnomad AFR exome
AF:
0.000925
Gnomad AMR exome
AF:
0.00154
Gnomad ASJ exome
AF:
0.0201
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.000131
Gnomad FIN exome
AF:
0.000185
Gnomad NFE exome
AF:
0.00159
Gnomad OTH exome
AF:
0.00460
GnomAD4 exome
AF:
0.00149
AC:
2176
AN:
1459716
Hom.:
9
Cov.:
31
AF XY:
0.00152
AC XY:
1106
AN XY:
726312
show subpopulations
Gnomad4 AFR exome
AF:
0.00132
Gnomad4 AMR exome
AF:
0.00175
Gnomad4 ASJ exome
AF:
0.0207
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.000174
Gnomad4 FIN exome
AF:
0.0000749
Gnomad4 NFE exome
AF:
0.00114
Gnomad4 OTH exome
AF:
0.00335
GnomAD4 genome
AF:
0.00150
AC:
228
AN:
151960
Hom.:
0
Cov.:
32
AF XY:
0.00136
AC XY:
101
AN XY:
74256
show subpopulations
Gnomad4 AFR
AF:
0.00113
Gnomad4 AMR
AF:
0.00164
Gnomad4 ASJ
AF:
0.0176
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.0000949
Gnomad4 NFE
AF:
0.00125
Gnomad4 OTH
AF:
0.00427
Alfa
AF:
0.00211
Hom.:
3
Bravo
AF:
0.00176
TwinsUK
AF:
0.00216
AC:
8
ALSPAC
AF:
0.00130
AC:
5
ESP6500AA
AF:
0.000681
AC:
3
ESP6500EA
AF:
0.00372
AC:
32
ExAC
AF:
0.00158
AC:
192
Asia WGS
AF:
0.000577
AC:
2
AN:
3478
EpiCase
AF:
0.00142
EpiControl
AF:
0.00261

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:2Benign:6
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not provided Uncertain:2Benign:3
Likely benign, no assertion criteria providedclinical testingGenome Diagnostics Laboratory, University Medical Center Utrecht-- -
Likely benign, criteria provided, single submitterclinical testingCeGaT Center for Human Genetics TuebingenJan 01, 2019- -
Likely benign, no assertion criteria providedclinical testingClinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center-- -
Uncertain significance, criteria provided, single submitterclinical testingGeneDxAug 24, 2017The V1222I variant in the PTPRC gene has not been reported previously as a pathogenic variant, nor as a benign variant, to our knowledge. The V1222I variant is observed in 164/66528 (0.247%) alleles from individuals of non-Finnish European background in the ExAC dataset, and no individuals are reported to be homozygous (Lek et al., 2016). The V1222I variant is a conservative amino acid substitution, which is not likely to impact secondary protein structure as these residues share similar properties. This substitution occurs at a position where amino acids with similar properties to Valine are tolerated across species. In silico analysis predicts this variant likely does not alter the protein structure/function. We interpret V1222I as a variant of uncertain significance. -
Uncertain significance, criteria provided, single submitterclinical testingARUP Laboratories, Molecular Genetics and Genomics, ARUP LaboratoriesJun 23, 2017The p.Val1224Ile variant has not been reported in the scientific medical literature or gene specific variant databases. This variant (rs150672767) is listed in the Exome Aggregation Consortium with an overall allele frequency of 0.16 percent. Valine at codon 1224 is weakly conserved considering 10 species (Alamut software v2.7.1), and Orangutan, Rhesus, Baboon, Mouse and Xenopus tropicalis all have isoleucine, suggesting that this amino acid change may be evolutionary tolerated. Additionally, computational analyses do not agree in their assessment of the impact on the protein (PolyPhen2: benign, SIFT: tolerated, and Mutation Taster: disease causing). Thus, even though the conservation and computational data suggest that this variant may represent a benign polymorphism, the clinical significance of p.Val1224Ile variant cannot be determined with certainty. Pathogenic variants in PTPRC are causative for severe combined immunodeficiency (MIM: 608971), and are inherited in autosomal recessive manner. Thus, even if p.Val1224Ile was subsequently determined to be pathogenic, based on the available information, this patient would be a carrier, and may be affected if a second pathogenic PTPRC variant is present on the opposite chromosome but could not be detected by this assay (eg, deep intronic variants, or regulatory region variants). -
not specified Benign:1
Benign, criteria provided, single submitterclinical testingWomen's Health and Genetics/Laboratory Corporation of America, LabCorpJul 12, 2022- -
PTPRC-related disorder Benign:1
Benign, no assertion criteria providedclinical testingPreventionGenetics, part of Exact SciencesSep 26, 2019This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -
Immunodeficiency 104 Benign:1
Benign, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpJan 31, 2024- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.059
BayesDel_addAF
Benign
-0.36
T
BayesDel_noAF
Benign
-0.30
CADD
Benign
0.0030
DANN
Benign
0.26
Eigen
Benign
-1.9
Eigen_PC
Benign
-1.9
FATHMM_MKL
Benign
0.040
N
LIST_S2
Benign
0.58
T;T
M_CAP
Uncertain
0.11
D
MetaRNN
Benign
0.0049
T;T
MetaSVM
Benign
-0.82
T
PrimateAI
Benign
0.25
T
REVEL
Uncertain
0.35
Sift4G
Benign
0.55
T;T
Vest4
0.097
MVP
0.25
MPC
0.14
ClinPred
0.0021
T
GERP RS
-6.4
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.1
Varity_R
0.015
gMVP
0.11

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs150672767; hg19: chr1-198725059; COSMIC: COSV99049535; COSMIC: COSV99049535; API